Archives
Stockholm, Sweden, May 29, 2026. The number of ordinary shares, class C shares and votes in Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) changed during May as a result of the exercise of employee stock options granted under the 2022–2026 employee stock option program. The total number of shares in the Company […]
Stockholm den 19 maj 2026. Egetis Therapeutics AB (publ) (”Egetis” eller ”Bolaget”) (NASDAQ Stockholm: EGTX) meddelade idag att Bolaget deltar i den årliga konferensen som arrangeras av International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2026, som äger rum den 17–20 maj 2026 i Philadelphia, Pennsylvania, USA. ISPOR är en ledande global konferens inom hälsoekonomi […]
Stockholm, Sweden, May 19, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced its participation in the annual conference of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2026, taking place May 17 to 20, 2026, in Philadelphia, PA, USA. ISPOR is a leading global conference for health economics […]
Stockholm den 13 maj, 2026. Egetis Therapeutics AB (publ) (”Egetis” eller ”Bolaget”) (Nasdaq Stockholm: EGTX) meddelade idag att medlemmar i Bolagets ledningsgrupp den 11 maj utnyttjade personaloptioner som de tilldelats i personaloptionsprogrammet 2022-2026. Detta program har ett slutdatum för utnyttjande av teckningsoptioner den 15 juni 2026. Om dessa optioner inte utnyttjas senast 15 juni 2026 […]
Stockholm, May 13, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) announces that on May 11, 2026, members of the Company’s executive management team exercised employee stock options granted under the employee stock option program (ESOP) 2022–2026. The final date for the exercise of options under ESOP 2022–2026 is June 15, […]
Stockholm den 7 maj, 2026. Egetis Therapeutics AB (publ) (”Egetis” eller ”Bolaget”) (Nasdaq Stockholm: EGTX) meddelade idag att Bolaget planerar att delta vid följande kommande medicinska konferenser under 2026: American Academy of Cerebral Palsy and Developmental Medicine (AACPDM)Philadelphia, PA, USA British Thyroid Association (BTA)London, UK Child Neurology Society (CNS)Montreal, Kanada European Society for Paediatric Endocrinology […]
Stockholm, May 7, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) today announced that the Company is planning to participate in several upcoming medical conferences in 2026, including: American Academy of Cerebral Palsy and Developmental Medicine (AACPDM)Philadelphia, PA, USA British Thyroid Association (BTA)London, UK Child Neurology Society (CNS)Montreal, Canada European Society […]
Stockholm den 5 maj 2026. Egetis Therapeutics AB (publ) (”Egetis” eller ”Bolaget”) (Nasdaq Stockholm: EGTX) meddelade idag att United States Patent and Trademark Office (USPTO) har beviljat patent nr US 12 611 383 B1 avseende Bolagets patentansökan nr 19/261,360 med titeln “Pharmaceutical Compositions for Treating MCT8 Deficiency”. Det beviljade patentet ger skydd för en ny sammansättning som innehåller […]
Stockholm, Sweden, May 5, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced that the United States Patent and Trademark Office (USPTO) granted Patent No. US 12611383B1 for the Company’s patent application No. 19/261,360 entitled “Pharmaceutical Compositions for Treating MCT8 Deficiency”. The newly granted patent provides protection for a novel […]
Stockholm, den 30 april 2026 – Egetis Therapeutics AB (publ) (”Egetis” eller ”Bolaget”) (Nasdaq Stockholm: EGTX) meddelade i dag att Bolaget kommer att delta vid Pediatric Endocrine Society (PES) Annual Meeting, som hålls den 30 april–3 maj 2026 i San Francisco, Kalifornien, USA. I samband med mötet kommer Egetis att delta i vetenskapliga och informationsrelaterade […]